Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.
Nikhil Neelkantan, Alina Mikhaylova, Adam Michael Stewart, Raymond Arnold, Visar Gjeloshi, Divya Kondaveeti, Manoj K Poudel, Allan V. Kalueff
ACS Chemical Neuroscience August 6, 2013 DOI: 10.1021/cn400090q (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Anxiety |
| Keywords | Animals Zebrafish Disease models, animal Hallucinogens Psychotropic drugs Drug evaluation, preclinical Behavior, animal Motor activity Social behavior Cognition Reward Psychopharmacology Phenotype Biomedical research Biomarkers |
| Key findings | The authors argue that zebrafish, with their genetic and physiological homology to humans, robust behaviors, and cost effectiveness, are valuable preclinical models for screening hallucinogens and studying drug-induced phenotypes, and they evaluate the potential of these models to translate to human drug-induced states. |
Abstract
Among different classes of psychotropic drugs, hallucinogenic agents exert one of the most prominent effects on human and animal behaviors, markedly altering sensory, motor, affective, and cognitive responses. The growing clinical and preclinical interest in psychedelic, dissociative, and deliriant hallucinogens necessitates novel translational, sensitive, and high-throughput in vivo models and screens. Primate and rodent models have been traditionally used to study cellular mechanisms and neural circuits of hallucinogenic drugs' action. The utility of zebrafish ( Danio rerio ) in neuroscience research is rapidly growing due to their high physiological and genetic homology to humans, ease of genetic manipulation, robust behaviors, and cost effectiveness. Possessing a fully characterized genome, both adult and larval zebrafish are currently widely used for in vivo screening of various psychotropic compounds, including hallucinogens and related drugs. Recognizing the growing importance of hallucinogens in biological psychiatry, here we discuss hallucinogenic-induced phenotypes in zebrafish and evaluate their potential as efficient preclinical models of drug-induced states in humans.
Comparable studies
Other narrative reviews on anxiety, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Mindfulness-based interventions: an overall review General (healthcare, schools, workplace) | 2021 | Review | |
| A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders | 2017 | Review and consensus statement | |
| Sudarshan Kriya Yogic Breathing in the Treatment of Stress, Anxiety, and Depression: Part II—Clinical Applications and Guidelines | 2005 | Review | |
| Mindfulness Meditation and Psychopathology | 2018 | Review | |
| Management of Treatment-Resistant Depression: Challenges and Strategies | 2020 | Review |
Citations in the library
Cited by 17
- Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models ACS Chemical Neuroscience September 25, 2018
- High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin Molecular Psychiatry January 17, 2024
- Exposure to ayahuasca induces developmental and behavioral alterations on early life stages of zebrafish Chemico-Biological Interactions August 4, 2018
- Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models Zebrafish March 22, 2016
- Zebrafish and Artemia salina in vivo evaluation of the recreational 25C-NBOMe drug demonstrates its high toxicity. Toxicology Reports 2021
and 12 more in the library
Cites 57
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder The Journal of Clinical Psychiatry November 15, 2006
- Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences September 3, 2002
- The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology July 19, 2010
- Serotonin research: contributions to understanding psychoses TIPS - Trends in Pharmacological Sciences August 1, 2008
and 52 more in the library